

KraneShares MSCI All China Health Care Index ETF

Ticker: KURE

Principal Listing Exchange: NYSE Arca

Semi-Annual Shareholder Report: September 30, 2025

This semi-annual shareholder report contains important information about the KraneShares MSCI All China Health Care Index ETF (the "Fund") for the period from April 1, 2025 to September 30, 2025. You can find additional information about the Fund at <https://kraneshares.com/kure/>. You can also request this information by contacting us at 1-855-857-2638.

What were the Fund costs for the last six months?

(based on a hypothetical \$10,000 investment)

Fund Name	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment
KraneShares MSCI All China Health Care Index ETF	\$38	0.65%

Key Fund Statistics as of September 30, 2025

Total Net Assets	Number of Holdings	Total Advisory Fees Paid	Portfolio Turnover Rate
\$110,997,710	55	\$305,524	48%

What did the Fund invest in?

Industry Weightings*	Top Ten Holdings																						
<div>Pharmaceuticals 34.8%</div> <div>Biotechnology 31.0%</div> <div>Life Sciences Tools & Services 17.7%</div> <div>Health Care Equipment & Supplies 10.4%</div> <div>Health Care Providers & Services 5.9%</div>	<table><thead><tr><th>Holding Name</th><th>Percentage of Total Net Assets</th></tr></thead><tbody><tr><td>BeiGene Medicines</td><td>9.1%</td></tr><tr><td>Jiangsu Hengrui Pharmaceuticals, Cl A</td><td>7.6%</td></tr><tr><td>Wuxi Biologics Cayman</td><td>7.3%</td></tr><tr><td>Innovent Biologics</td><td>7.3%</td></tr><tr><td>Sino Biopharmaceutical</td><td>4.6%</td></tr><tr><td>Shenzhen Mindray Bio-Medical Electronics, Cl A</td><td>4.5%</td></tr><tr><td>WuXi AppTec, Cl A</td><td>4.5%</td></tr><tr><td>Akeso</td><td>3.8%</td></tr><tr><td>3SBio</td><td>3.2%</td></tr><tr><td>CSPC Pharmaceutical Group</td><td>2.9%</td></tr></tbody></table>	Holding Name	Percentage of Total Net Assets	BeiGene Medicines	9.1%	Jiangsu Hengrui Pharmaceuticals, Cl A	7.6%	Wuxi Biologics Cayman	7.3%	Innovent Biologics	7.3%	Sino Biopharmaceutical	4.6%	Shenzhen Mindray Bio-Medical Electronics, Cl A	4.5%	WuXi AppTec, Cl A	4.5%	Akeso	3.8%	3SBio	3.2%	CSPC Pharmaceutical Group	2.9%
Holding Name	Percentage of Total Net Assets																						
BeiGene Medicines	9.1%																						
Jiangsu Hengrui Pharmaceuticals, Cl A	7.6%																						
Wuxi Biologics Cayman	7.3%																						
Innovent Biologics	7.3%																						
Sino Biopharmaceutical	4.6%																						
Shenzhen Mindray Bio-Medical Electronics, Cl A	4.5%																						
WuXi AppTec, Cl A	4.5%																						
Akeso	3.8%																						
3SBio	3.2%																						
CSPC Pharmaceutical Group	2.9%																						

Material Fund Changes

There were no material changes during the reporting period.

Additional Information

For additional information about the Fund, including its prospectus, financial information, holdings, and proxy voting information, visit <https://kraneshares.com/kure/>.

Householding

You may have consented to receive one copy of a shareholder report at your address if you and one or more individuals in your home have multiple accounts at the same address. This practice is commonly called "householding" and is intended to reduce expenses. If you wish to change your householding status or receive individual copies of your shareholder report, please contact us at 1-855-857-2638 or your financial intermediary.

